TALWIN COMPOUND
Clinical safety rating
cautionComprehensive clinical and safety monograph for TALWIN COMPOUND (TALWIN COMPOUND).
TALWIN COMPOUND contains pentazocine, a mixed agonist-antagonist at opioid receptors with partial agonist activity at mu receptors and full agonist activity at kappa receptors, and naloxone, an opioid antagonist that reduces abuse potential by precipitating withdrawal in opioid-dependent individuals when injected. The combination provides analgesia through pentazocine's central and peripheral opioid receptor activation, while naloxone is not absorbed orally but prevents intravenous abuse.
| Metabolism | Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; naloxone is metabolized primarily by glucuronidation in the liver. |
| Excretion | Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30% as conjugates. |
| Half-life | Pentazocine: 2-3 hours; naloxone: 1-1.5 hours. Clinical context: Repeated dosing may prolong effective half-life due to tissue accumulation. |
| Protein binding | Pentazocine: 60-70% bound to albumin and alpha-1-acid glycoprotein; naloxone: 40-50% bound to albumin. |
| Volume of Distribution | Pentazocine: 4-5 L/kg (extensive tissue distribution); naloxone: 2-3 L/kg (rapid distribution to CNS). |
| Bioavailability | Oral: 20-30% (first-pass metabolism); IM/IV: 100%. |
| Onset of Action | Oral: 15-30 minutes; IM: 15-20 minutes; IV: 2-3 minutes. |
| Duration of Action | Oral: 3-4 hours; IM/IV: 2-3 hours (analgesic effect). Note: Naloxone component may shorten duration in opioid-tolerant patients. |
| Molecular Weight | Pentazocine: 285.42 g/mol; Aspirin: 180.16 g/mol (combination product). |
1-2 tablets (each tablet contains pentazocine HCl 12.5 mg and aspirin 325 mg) orally every 3-4 hours as needed, not to exceed 6 tablets per day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: administer every 4-6 hours; GFR 10-29 mL/min: administer every 6-8 hours; GFR <10 mL/min: not recommended due to aspirin component. |
| Liver impairment | Child-Pugh class B: reduce dose by 50% and extend interval to every 6 hours; Child-Pugh class C: avoid use due to risk of pentazocine accumulation and aspirin hepatotoxicity. |
| Pediatric use | Not recommended for pediatric use due to aspirin risk of Reye's syndrome; pentazocine safety not established. |
| Geriatric use | Start with 1 tablet every 4-6 hours; monitor for CNS effects (dizziness, sedation) and GI bleeding; reduce dose if renal impairment present. |
| 1st trimester | Avoid; teratogenic risk (pentazocine/aspirin) – see aspirin: first trimester linked to neural tube defects; pentazocine limited data. |
| 2nd trimester | Avoid; aspirin may cause premature closure of ductus arteriosus and oligohydramnios; pentazocine neonatal respiratory depression. |
| 3rd trimester | Contraindicated; aspirin increases risk of maternal/neonatal bleeding, premature ductus closure; pentazocine neonatal withdrawal. |
Clinical note
Comprehensive clinical and safety monograph for TALWIN COMPOUND (TALWIN COMPOUND).
| Placental transfer | Both aspirin and pentazocine cross the placenta freely. |
| Breastfeeding | Aspirin and pentazocine are excreted into breast milk. Aspirin may cause Reye's syndrome in infants; pentazocine may cause neonatal sedation and respiratory depression. Avoid use in breastfeeding. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects due to aspirin component (pentazocine 12.5 mg + aspirin 325 mg). Second trimester: Risk of oligohydramnios and fetal renal impairment from aspirin. Third trimester: Premature closure of ductus arteriosus, persistent pulmonary hypertension, intrauterine growth restriction, and increased bleeding risk due to aspirin. Pentazocine may cause neonatal respiratory depression if used near term. |
| Fetal Monitoring | Monitor fetal growth, amniotic fluid volume (ultrasound), ductus arteriosus patency (fetal echocardiography) if used in third trimester. Monitor maternal coagulation parameters and renal function. In neonate, observe for respiratory depression and bleeding. |
| Fertility Effects | Aspirin may inhibit prostaglandin synthesis, potentially impairing ovulation and implantation; pentazocine may disrupt hypothalamic-pituitary axis causing menstrual irregularities. Reversible upon discontinuation. |
■ FDA Black Box Warning
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and CYTOCHROME P450 3A4 INTERACTION. Addiction, Abuse, and Misuse: TALWIN COMPOUND exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly. Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. Accidental Ingestion: Accidental ingestion of even one dose of TALWIN COMPOUND, especially by children, can result in a fatal overdose. Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in withdrawal in the neonate, which may be life-threatening if not recognized and treated. Cytochrome P450 3A4 Interaction: The concomitant use of TALWIN COMPOUND with all cytochrome P450 3A4 inhibitors may result in an increase in pentazocine plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in pentazocine plasma concentration. Monitor patients receiving TALWIN COMPOUND and any CYP3A4 inhibitor or inducer.
| Serious Effects |
Hypersensitivity to pentazocine, aspirin, or NSAIDsHemophilia or bleeding disordersActive peptic ulcer diseaseSevere hepatic impairmentThird trimester pregnancyBreastfeedingChildren with viral illnesses (Reye's syndrome risk)Severe respiratory depressionConcomitant MAOI therapy
| Precautions | Addiction, abuse, and misuse, Life-threatening respiratory depression, Neonatal opioid withdrawal syndrome, Risks from concomitant use with benzodiazepines or other CNS depressants, Drug dependence, Increased intracranial pressure, Seizures in patients with seizure disorders, Abrupt discontinuation, Risks of driving and operating machinery |
| Food/Dietary | Avoid alcohol due to additive CNS depression and increased GI irritation. Take with food or milk to minimize aspirin-related gastric irritation. Avoid high-dose vitamin C (increases aspirin absorption). No other significant food interactions. |
| Clinical Pearls | Talwin Compound contains pentazocine (opioid partial agonist) and aspirin (NSAID). Monitor for opioid-induced respiratory depression, especially in elderly or opioid-naive patients. Pentazocine may cause psychotomimetic effects (e.g., hallucinations, dysphoria) at higher doses. Avoid in patients with acute MI or those on MAOIs. Aspirin component increases bleeding risk; avoid with anticoagulants or history of peptic ulcer. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not crush or chew tablets; swallow whole. · Avoid alcohol while taking this medication. · May cause dizziness or drowsiness; do not drive until you know how it affects you. · Stop and seek medical help if you have signs of bleeding (e.g., black stools, vomiting blood) or allergic reaction (e.g., hives, difficulty breathing). · Use for short-term pain relief; long-term use may lead to dependence or kidney damage. · Store safely out of reach of children and dispose of unused medication properly. |
Loading safety data…